文献速递消化与肝胆胰病理细胞病理与分子病理

p53、SMAD4及新型标志物PON2在胰腺导管腺癌FNA诊断中的价值

Diagnostic utility of p53, SMAD4, and the novel biomarker PON2 in FNA of pancreatic ductal adenocarcinoma.
PubMed 文献 · Cancer Cytopathol · 2025-01-01

该回顾性研究评估p53、SMAD4和PON2免疫表达在胰腺导管腺癌(PDAC)细针穿刺(FNA)诊断中的效用。在原发队列(10例良性、23例PDAC)中,p53异常表达和SMAD4缺失分别见于74%和48%的PDAC,联合检测AUC达0.96;PON2在PDAC中表达显著高于良性(p < .001)。结论认为p53联合SMAD4免疫染色有助于改善FNA诊断,PON2可能作为潜在生物标志物。

要点

  • p53异常表达和SMAD4缺失在PDAC中分别占74%和48%,良性病变均无表达。
  • p53联合SMAD4的AUC为0.96,优于任一标志物单独使用(AUC=0.87和0.74)。
  • PON2在PDAC中H-score范围为110至290,显著高于良性病变(p < .001)。

核心结论

  • 联合p53和SMAD4免疫染色可提高FNA对PDAC的诊断准确性,尤其在疑难病例中。
  • PON2在PDAC中差异表达,可能作为潜在生物标志物,需进一步研究。

研究设计与样本

  • 回顾性研究,从病理档案中选取细胞学病例,要求细胞块材料充足。
  • 原发队列:10例良性病变和23例PDAC,进行p53、SMAD4和PON2免疫染色。
  • 不确定队列:3例非典型和17例可疑病例,仅进行p53和SMAD4免疫染色。
  • p53和SMAD4采用定性评估,PON2采用半定量H-score评估。

主要发现

  • 原发队列中,p53异常表达见于74%的PDAC,SMAD4缺失见于48%的PDAC,良性病变均无表达。
  • p53联合SMAD4的AUC为0.96,优于p53单独(AUC=0.87)和SMAD4单独(AUC=0.74)。
  • 不确定队列中,17例恶性随访病例中13例(76%)出现p53异常表达或SMAD4缺失。
  • PON2在PDAC中H-score范围为110至290,显著高于良性病例(p < .001)。
  • 两例p53野生型且SMAD4表达完整的PDAC病例显示强PON2表达。

关键数值与推荐

  • p53异常表达和SMAD4缺失在PDAC中的比例分别为74%和48%,良性病变均为0%。
  • p53联合SMAD4的AUC为0.96,p53单独AUC为0.87,SMAD4单独AUC为0.74。
  • PON2在PDAC中的H-score范围为110至290,与良性病例比较p < .001。

临床怎么用

  • 在FNA细胞块中联合应用p53和SMAD4免疫染色,可辅助PDAC诊断,尤其对不确定病例。
  • PON2免疫染色可作为潜在补充标志物,但尚未推荐常规使用。

局限性

  • PON2仅在原发队列中评估,未在不确定队列中验证。
  • PON2为半定量H-score评估,检测标准化需进一步确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate cytologic diagnosis of pancreatic ductal adenocarcinoma (PDAC) remains challenging. In this retrospective study, the authors assessed the utility of p53, SMAD4, and paraoxonase-2 (PON2) expression in fine-needle aspiration (FNA) diagnosis of PDAC. METHODS: Cytologic cases with sufficient cell block material were retrieved from pathology archives. p53 and SMAD4 immunostains were performed in two separate cohorts, primary cohort (10 benign and 23 PDAC cases) and indeterminate cohort (3 atypical and 17 suspicious cases). PON2 immunostain was performed in the primary cohort (10 benign and 23 PDAC cases). p53 and SMAD4 immunostains were qualitatively assessed and PON2 test was evaluated by semiquantitative H-score. RESULTS: In the primary cohort, p53 aberrant expression and SMAD4 loss were identified in 74% and 48% of PDAC cases compared to none in benign lesions. The combination of p53 and SMAD4 achieved a superior performance with an area under the curve (AUC) value of 0.96, compared to either marker alone (AUC = 0.87 and 0.74, respectively). In the indeterminate cohort, p53 aberrant expression or SMAD4 loss was seen in 13 of 17 (76%) malignant follow-up cases. PON2 was variably expressed in PDAC cases with H-scores ranging from 110 to 290, significantly higher in PDACs compared to benign cases (p < .001). Furthermore, strong PON2 expression was seen in two PDAC cases with wild-type p53 and intact SMAD4 expression. CONCLUSIONS: Combined p53 and SMAD4 immunostaining could help improve FNA diagnosis of PDACs, particularly in challenging cases. PON2 is differentially expressed in PDAC cases and may serve as a potential biomarker, warranting further investigation.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Yang R, Gereg C, Olave MC, et al. Diagnostic utility of p53, SMAD4, and the novel biomarker PON2 in FNA of pancreatic ductal adenocarcinoma. Cancer Cytopathol. 2025. PMID: 41159799. doi:10.1002/cncy.70058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。